Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 72Cytarabine 61fludarabine phosphate 48venetoclax 42Peripheral Blood Stem Cell Transplantation 37fludarabine 34Busulfan 31Methotrexate 29Cyclosporine 29Mycophenolic Acid 28Filgrastim 27Azacitidine 27Antilymphocyte Serum 26Whole-Body Irradiation 22Etoposide 21Radiotherapy 20Melphalan 20Tacrolimus 19Rituximab 19Dexamethasone 16Methylprednisolone 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Vincristine 14Cord Blood Stem Cell Transplantation 14Doxorubicin 13Clofarabine 11Mitoxantrone 10ibrutinib 9blinatumomab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × zosuquidar trihydrochloride × Other hematologic neoplasm × Clear all
NCT00129168 2008-04-01

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Kanisa Pharmaceuticals

Phase 1/2 Completed
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT00233909 2008-04-01

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Kanisa Pharmaceuticals

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡